HomeMarket NewsLeerink Predicts Structure Therapeutics Stock as "Undervalued" in Growing Oral GLP-1 Diabetes...

Leerink Predicts Structure Therapeutics Stock as “Undervalued” in Growing Oral GLP-1 Diabetes Drug Market

Actionable Trade Ideas

always free

Weight loss pills. Obesity treatment. Overweight problems.

Alexey Krukovsky


Leerink, an investment bank specializing in healthcare, has stated that it believes Structure Therapeutics (NASDAQ:GPCR) is currently β€œsignificantly undervalued.” Leerink observes an β€œextraordinary” total addressable market for oral GLP-1 diabetes drugs, presenting a lucrative opportunity for Structure Therapeutics. The investment bank is particularly optimistic about the company’s GLP-1 drug candidate, GSBR-1290, following the release of Phase 1 data. Leerink believes this drug could be a strong competitor to Eli Lilly’s (LLY) GLP-1 oral drug candidate, forglipron. Furthermore, Leerink predicts the global peak potential sales for orally administered incretin drugs to be between $50 billion and $75 billion.

Price Target:

Based on their analysis, Leerink has raised the price target for Structure Therapeutics stock from $46 to $97.

Market Reaction:

As a result of the positive Phase 1 data release, Structure Therapeutics shares experienced a sharp increase in value. The company, which went public in February, is uniquely positioned to capitalize on the growing demand for oral GLP-1 diabetes drugs.

More on Structure Therapeutics

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.